AngioDynamics, Inc. (ANGO) recently announced that it has entered into a settlement agreement with Becton, Dickinson and Company (BDX) , popularly known as BD, to resolve all outstanding patent litigation with C.R. Bard, Inc., an affiliate of BD.AngioDynamics is likely to benefit from the settlement of this prolonged legal dispute to a successful resolution as it will lower the company’s ongoing legal expenses and terminate more than 10-year distraction.Price PerformanceFor the past six months, ANGO’s share ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4, 2024. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the ...

Company Performance - AngioDynamics' stock closed at $5.37, reflecting a decrease of -0.74% from the previous trading day, which is less than the S&P 500's daily loss of 0.65% [1] - The stock has declined by 12.32% over the past month, underperforming the Medical sector's gain of 1.98% and the S&P 500's gain of 3.27% [1] - The upcoming earnings report is expected to show an EPS of -$0.14, a significant drop of 366.67% from the same quarter last year, with projected quarterly revenue of $76.71 million, down 4.96% year-over-year [1] Annual Projections - For the full year, earnings are projected at -$0.43 per share and revenue at $316.15 million, indicating changes of -616.67% and -6.67% respectively from the prior year [2] - Recent analyst estimate revisions are crucial as they reflect near-term business trends, with positive revisions indicating confidence in the company's performance [2] Zacks Rank and Industry Performance - AngioDynamics currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having decreased by 10.9% in the past month [3] - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 56, placing it in the top 23% of over 250 industries [3] - The Zacks Industry Rank evaluates the strength of industry groups, showing that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [3]

AngioDynamics (ANGO) closed at $5.67 in the latest trading session, marking a -1.39% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.65% for the day. On the other hand, the Dow registered a loss of 0.18%, and the technology-centric Nasdaq decreased by 1.16%.The the stock of medical device maker has fallen by 6.5% in the past month, lagging the Medical sector's gain of 3.18% and the S&P 500's gain of 3.4%.The investment community will be paying close attention to th ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Virtual Healthcare MedTech ...

In the latest market close, AngioDynamics (ANGO) reached $5.99, with a +1.7% movement compared to the previous day. The stock's change was less than the S&P 500's daily gain of 2.11%. Elsewhere, the Dow gained 1.18%, while the tech-heavy Nasdaq added 2.96%.The the stock of medical device maker has fallen by 1.83% in the past month, lagging the Medical sector's gain of 3.98% and the S&P 500's gain of 3.08%.The investment community will be closely monitoring the performance of AngioDynamics in its forthcoming ...

AngioDynamics, Inc. (ANGO) recently announced the completion of the sale of its PICC and Midline product portfolios to Spectrum Vascular for $45 million in cash.AngioDynamics' PICC, Midline, and tip location products are the subject of the transaction. During AngioDynamics' fiscal 2023, the combined portfolio of products contributed more than $43.5 million in revenues annually.Price PerformanceFor the past six months, ANGO’s shares have declined 28.1% against the industry’s rise of 7.8%. The S&P 500 increas ...

AngioDynamics (ANGO) closed the latest trading day at $6.17, indicating a +1.31% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily gain of 0.58%. Elsewhere, the Dow gained 0.91%, while the tech-heavy Nasdaq added 0.3%.Coming into today, shares of the medical device maker had gained 3.4% in the past month. In that same time, the Medical sector gained 2.39%, while the S&P 500 gained 4.61%.Investors will be eagerly watching for the performance of AngioDynamics in ...

Company Performance - AngioDynamics (ANGO) stock closed at $6.09, reflecting a -0.98% change from the previous day, underperforming the S&P 500 which gained 0.57% [1] - Over the last month, AngioDynamics shares increased by 1.49%, lagging behind the Medical sector's gain of 2.05% and the S&P 500's gain of 5.07% [1] - The upcoming earnings release is anticipated, with projected earnings per share (EPS) of -$0.12, indicating a 300% decrease from the same quarter last year, and expected revenue of $78.23 million, a 3.08% decline year-over-year [1] Full Year Estimates - For the full year, analysts expect earnings of -$0.39 per share and revenue of $320.79 million, representing changes of -550% and -5.3% from the previous year [2] - Recent changes to analyst estimates may reflect short-term business dynamics, with positive adjustments indicating a favorable outlook on the company's health and profitability [2] Zacks Rank and Industry Performance - The Zacks Rank system rates AngioDynamics at 4 (Sell), with the consensus EPS estimate remaining unchanged over the last 30 days [3] - The Medical - Instruments industry, part of the Medical sector, holds a Zacks Industry Rank of 158, placing it in the bottom 38% of over 250 industries [3] - The Zacks Industry Rank is based on the average Zacks Rank of individual stocks, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [3]

Company Overview - AngioDynamics, Inc. (ANGO) received FDA clearance for the Auryon XL Catheter, a 225-cm radial access catheter, for use with the Auryon Atherectomy System in treating Peripheral Arterial Disease (PAD) [1] - The Auryon XL Catheter expands access points in atherectomy procedures, potentially reducing access site complications and accelerating patient recovery [1][4] - The catheter is available in sizes of 0.9 mm and 1.5 mm, and may decrease serious bleeding occurrences compared to traditional femoral access [4] - The Auryon XL Catheter is the first non-orbital atherectomy device, setting a new benchmark for laser atherectomy technology [4] - AngioDynamics plans to launch the Auryon XL Catheter in a full market rollout in February 2024 after a limited market launch in January [4][5] Financial Performance - Over the past six months, ANGO's shares have decreased by 31.0%, while the industry declined by 5.0% and the S&P 500 increased by 6.6% [2] Industry Insights - The global atherectomy system market was valued at $621.8 million in 2021 and is projected to grow at a rate of 6.0%, expected to exceed $1.1 billion by 2031 [6] - The growth in the atherectomy system market is driven by the increasing demand for less invasive surgical procedures and the rising prevalence of cardiovascular diseases [6]